Canaccord lowered the firm’s price target on Zimmer Biomet (ZBH) to $101 from $115 and keeps a Hold rating on the shares. The firm updated its model where they lowered their EPS estimates with the P28 acquisition and efforts to fall more in line with the current stock price post earnings with a slightly higher applied discount to the comp group.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ZBH:
- Zimmer Biomet participates in a conference call with JPMorgan
- Zimmer Biomet price target lowered to $125 from $140 at Citizens JMP
- Zimmer Biomet price target lowered to $101 from $113 at Truist
- Zimmer Biomet price target lowered to $95 from $115 at Morgan Stanley
- Zimmer Biomet price target lowered to $112 from $125 at RBC Capital